Publications by authors named "Martin-Rodriguez Mª Mar"
Article Synopsis
- A study examined the persistence of adalimumab biosimilars compared to the original drug, analyzing data from 104 patients grouped by the type of medication received.
- Results showed that the biosimilars had higher persistence rates after 12 months, with no significant differences in mild adverse events across groups, but a higher occurrence of severe events in those who switched from the original to the biosimilar.
- Overall, biosimilars proved to be a cost-effective and clinically equivalent option for treating inflammatory bowel disease (IBD), without negatively impacting patient outcomes, supporting their use in healthcare sustainability.
Effectiveness and safety of ustekinumab in bio-naïve Crohn's disease patients: a multicentre observational retrospective study.
Valdés Delgado Teresa Olmedo Martín Rául Iborra Marisa Herrera de Guisé Claudia Fuentes-Valenzuela Esteban Martín-Rodríguez Mª Mar Manceñido Marcos Noemí Lázaro Sáez Marta
Therap Adv Gastroenterol
February 2023
Background: Clinical trials have demonstrated the efficacy and safety of ustekinumab in Crohn's disease (CD). However, more data are necessary on the effectiveness of ustekinumab in bio-naïve patients in real-life studies.
Objectives: The aim of our study was to evaluate the effectiveness and safety of ustekinumab in patients with CD refractory or intolerant to conventional therapy and without previous exposure to biological drugs.